Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New implant offers hope for stubborn back pain sufferers

NCT ID NCT06909292

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at a device called Nevro1, which is a titanium cage implanted in the sacroiliac joint to stabilize it and encourage bone fusion. Researchers wanted to see if it could safely reduce pain and improve function in 180 adults with chronic sacroiliac joint dysfunction. The main goals were pain relief, no serious side effects, and evidence of joint fusion at one and two years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nevro1 sacroiliac transfixing and fusion system (a titanium implant with bone graft to stabilize the joint)
What this could lead to
If successful, this device could offer a safe, lasting option for people with chronic sacroiliac joint pain who haven't found relief from other treatments.
What could go wrong
This is a post-market study, so the device is already approved. However, results may not apply to everyone, and risks include implant-related complications or lack of pain relief.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

180 people

The number who actually took part.

Started

Apr 2025

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Cohort will be selected from participating clinics

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Has medical insurance that covers this standard of care procedure and all other anticipated and unanticipated procedure-related care, and all coverage criteria required by insurer are met, which may include but are not limited to: * Has had low back and/or buttock pain for at least 6 months that is inadequately responsive to non-surgical care * Has a positive Fortin's test * Has a diagnosis of SIJ dysfunction (degenerative sacroiliitis or SI disruption) with pain elicited on at least 3 of 5 provocative tests (FABER, Gaenslen, Distraction, Thigh Thrust, Compression). * At least 75% reduction in pain for the expected duration of two anesthetics (on separate visits each with a different duration of action), and the ability to perform previously painful maneuvers, following an image-guided, contrast-enhanced intra-articular (diagnostic) SIJ injection * A trial of at least one therapeutic intra-articular SIJ injection (i.e. corticosteroid injection) 2. Has an ODI score ≥30% at enrollment 3. Has a SI joint pain score of at least 5 out of 10 on numerical rating scale at enrollment. 4. Be at least 21 years of age at enrollment 5. The patient's physician has decided that the best treatment for the patient's SIJ dysfunction is the Nevro1 SI Fixation System, and the patient has agreed to the treatment 6. Be willing and capable of giving written informed consent 7. Be mentally and physically able to comply with study-related requirements and procedures and attend all scheduled visits Exclusion Criteria: 1. Has current severe back pain due to other causes, such as lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, lumbar radicular pain, and lumbar vertebral body fracture 2. Has SIJ pain secondary to inflammatory conditions or other known sacroiliac pathology such as: Sacral dysplasia, inflammatory sacroiliitis (e.g., ankylosing spondylitis or other HLA-associated spondylo-arthropathy), tumor, infection, acute fracture, and crystal arthropathy 3. Has had a previous SIJ implant placement, including an allograft 4. Has had an injection with corticosteroid into the index SIJ within the last 30 days 5. Has had a sacral radiofrequency ablation within the last 6 months 6. Has a history of recent (\<1 year) major trauma to pelvis 7. Has previously diagnosed or suspected severe osteoporosis (defined as prior T-score \< -2.5 or history of osteoporotic fracture) 8. Has a chronic rheumatologic condition (e.g., rheumatoid arthritis) 9. Has a known allergy to titanium or titanium alloys 10. Has a current local or systemic infection that raises the risk of surgery 11. Is currently receiving or seeking short- or long-term worker's compensation related to the SI joint or low back pain, is currently receiving disability remuneration related to SI joint or low back pain, and/or is currently involved in injury litigation related to the SI joint or low back pain 12. Is participating in an investigational study or has been involved in an investigational study within 3 months prior to enrollment 13. Has any condition or anatomy that makes treatment with the Nevro1 SI Fixation System infeasible 14. Is taking a medication known to have detrimental effects on bone quality and soft tissue healing 15. Has a prominent neurologic condition that would interfere with physical therapy 16. Be pregnant or plan on becoming pregnant in the next two years. 17. Has a medical condition or pain in other area(s), not intended to be treated in this study, that could interfere with study procedures, accurate pain reporting, and/or confound evaluation of study endpoints, as determined by the Investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sacroiliac joint dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • AIRS Clinic

    Lodi, California, 95240, United States

  • Advanced Spine and Pain Specialists

    Spring, Texas, 77380, United States

  • Carolinas Pain Institute

    Winston-Salem, North Carolina, 27103, United States

  • Michigan Orthopaedic Surgeons

    Southfield, Michigan, 48033, United States

  • Procura Pain and Spine

    The Woodlands, Texas, 77384, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.